Generate realistic clinical trial synthetic data including study definitions, sites, subjects, visits, adverse events, efficacy assessments, and disposition...
Status: Active Development
TrialSim generates realistic synthetic clinical trial data for testing, training, and development purposes.
Use this skill when the user requests clinical trial data, CDISC-compliant datasets, or regulatory submission test data. This is the primary skill for generating realistic synthetic clinical trial data.
When to apply this skill:
Key capabilities:
For specific trial phases, therapeutic areas, or SDTM domains, load the appropriate skill from the tables below.
All data generated by TrialSim is synthetic and fictional. It must never be used for real clinical decisions, patient care, or regulatory submissions without explicit disclaimers.
Edge cases: If a user requests invalid visit windows, missing baseline assessments, or partial SDTM domains, flag the issue and suggest corrections. For unknown MedDRA terms, use the closest valid preferred term.
Activate TrialSim when user mentions:
| Topic | Skill | Description |
|---|---|---|
| Domain Knowledge | clinical-trials-domain.md | Core trial concepts, phases, regulatory |
| Recruitment | recruitment-enrollment.md | Screening funnel, enrollment patterns |
| Phase | Skill | Description |
|---|---|---|
| Phase 1 | phase1-dose-escalation.md | FIH, dose escalation, MTD (3+3, BOIN, CRM) |
| Phase 2 | phase2-proof-of-concept.md | POC, dose-ranging, futility (Simon's, MCP-Mod) |
| Phase 3 | phase3-pivotal.md | Pivotal registration trials, NDA/BLA |
| Domain | Skill | Description |
|---|---|---|
| DM | domains/demographics-dm.md | Subject demographics, treatment arms |
| AE | domains/adverse-events-ae.md | Adverse events with MedDRA coding |
| VS | domains/vital-signs-vs.md | Vital sign measurements |
| LB | domains/laboratory-lb.md | Laboratory results with LOINC |
| CM | domains/concomitant-meds-cm.md | Concomitant medications with ATC |
| EX | domains/exposure-ex.md | Study drug exposure, dose modifications |
| DS | domains/disposition-ds.md | Subject disposition, discontinuation |
| MH | domains/medical-history-mh.md | Medical history, comorbidities |
| RS/TR | therapeutic-areas/oncology.md | Tumor results / disease response (RECIST) |
| Domain Index | domains/README.md | All SDTM domains overview |
| Area | Skill | Key Endpoints |
|---|---|---|
| Oncology | therapeutic-areas/oncology.md | Tumor response (RECIST), ORR, PFS, OS |
| Cardiovascular | therapeutic-areas/cardiovascular.md | MACE, CV outcomes |
| CNS | therapeutic-areas/cns.md | Cognitive scales, imaging |
| CGT | therapeutic-areas/cgt.md | CAR-T, gene therapy |
| Topic | Skill | Description |
|---|---|---|
| RWE Overview | rwe/overview.md | RWE concepts, data sources |
| Synthetic Controls | rwe/synthetic-control.md | External control arm generation |
| Format | Skill | Use Case |
|---|---|---|
| SDTM | ../../formats/cdisc-sdtm.md | Regulatory submission |
| ADaM | ../../formats/cdisc-adam.md | Statistical analysis |
| Dimensional | ../../formats/dimensional-analytics.md | BI dashboards, analytics |
| JSON | Default | API integration |
| CSV | ../../formats/csv.md | Spreadsheet analysis |
| Resource | Location | Description |
|---|---|---|
| Canonical Models | ../../references/data-models.md#trialsim-models | 15 entity schemas (Subject, Study, Site, AE, etc.) |
| Dimensional Schema | ../../formats/dimensional-analytics.md#trialsim-clinical-trial-analytics | Star schema for BI (7 dims, 6 facts) |
| Code Systems | ../../references/code-systems.md | MedDRA, LOINC, ATC, ICD-10, SNOMED CT, RxNorm, NDC, NPI, HCPCS, CPT |
TrialSim uses 15 canonical entity schemas. See Data Models Reference for complete JSON schemas.
| Entity | SDTM Domain | Description |
|---|---|---|
| Subject | DM | Trial participant (extends Person) |
| Study | TS | Protocol definition |
| Site | - | Investigational site |
| TreatmentArm | TA | Study arm definition |
| VisitSchedule | TV | Protocol visits |
| ActualVisit | SV | Subject visit occurrence |
| Randomization | DM/SE | Subject randomization |
| AdverseEvent | AE | Safety events with MedDRA |
| Exposure | EX | Study drug dosing |
| ConcomitantMed | CM | Prior/concomitant meds with ATC |
| TrialLab | LB | Lab results with LOINC |
| EfficacyAssessment | RS/TR | Response assessments |
| MedicalHistory | MH | Pre-existing conditions |
| DispositionEvent | DS | Subject disposition |
| ProtocolDeviation | DV | Protocol deviations |
Study:
{
"study_id": "ABC-123-001",
"protocol_title": "A Phase 3, Randomized, Double-Blind Study...",
"phase": "Phase 3",
"therapeutic_area": "Oncology",
"indication": "Non-Small Cell Lung Cancer",
"sponsor": "Example Pharma Inc.",
"status": "Ongoing"
}
Subject (with cross-product linking):
{
"subject_id": "0001",
"usubjid": "ABC-123-001-001-0001",
"site_id": "001",
"patient_ref": "MRN-12345",
"screening_date": "2024-01-15",
"randomization_date": "2024-01-22",
"treatment_arm": "TRT",
"status": "Active"
}
TrialSim integrates with other HealthSim products for complete clinical trial data:
| From | To | Integration Pattern |
|---|---|---|
| PatientSim | TrialSim | Patient → Subject (add consent, randomization, protocol visits) |
| NetworkSim | TrialSim | Provider → Investigator (add credentials, training, delegation log) |
| PopulationSim | TrialSim | Demographics → Recruitment pool (geographic, demographic eligibility) |
Trial subjects are patients with additional trial-specific data:
Integration Pattern: Use PatientSim for baseline clinical characteristics. TrialSim adds protocol-specific assessments (RECIST, NYHA class changes), randomization, and SDTM-formatted data.
PopulationSim provides real-world reference data (CDC PLACES, SVI, ADI) for evidence-based trial planning, site selection, and FDA diversity compliance. When geographies are specified, TrialSim grounds feasibility estimates and enrollment projections in actual prevalence and demographic data.
See populationsim-integration.md for detailed data-driven planning patterns, reference data sources, and site selection examples.
All skill files complete: core skills, Phase 1-3, SDTM domains (DM, AE, VS, LB, CM, EX, DS, MH), therapeutic areas, and RWE.
Prompt: "Generate a Phase 3 oncology trial with 200 subjects"
Output:
{
"study": {
"study_id": "ONCO-2025-001",
"protocol_title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of ABC-123 in Advanced NSCLC",
"phase": "Phase 3",
"therapeutic_area": "Oncology",
"indication": "Non-Small Cell Lung Cancer",
"design": "Randomized, Double-Blind, Placebo-Controlled",
"primary_endpoint": "Overall Survival",
"target_enrollment": 200,
"arms": [
{ "arm_id": "A", "name": "ABC-123 + SOC", "allocation_ratio": 1 },
{ "arm_id": "B", "name": "Placebo + SOC", "allocation_ratio": 1 }
]
},
"sites": [
{ "site_id": "001", "name": "Memorial Cancer Center", "country": "USA", "enrolled": 25 },
{ "site_id": "002", "name": "University Oncology", "country": "USA", "enrolled": 22 }
],
"subjects": [
{
"subject_id": "001-0001",
"site_id": "001",
"arm": "A",
"status": "Active",
"randomization_date": "2025-01-15"
}
]
}
Prompt: "Generate adverse events for a 50-subject immunotherapy trial"
Output:
{
"domain": "AE",
"adverse_events": [
{
"USUBJID": "IO-001-0023",
"AESEQ": 1,
"AETERM": "Fatigue",
"AEDECOD": "Fatigue",
"AEBODSYS": "General disorders and administration site conditions",
"AESEV": "MILD",
"AESER": "N",
"AEREL": "POSSIBLY RELATED",
"AESTDTC": "2025-02-10",
"AEENDTC": "2025-02-18",
"AEOUT": "RECOVERED/RESOLVED"
},
{
"USUBJID": "IO-001-0007",
"AESEQ": 1,
"AETERM": "Immune-mediated colitis",
"AEDECOD": "Colitis",
"AEBODSYS": "Gastrointestinal disorders",
"AESEV": "SEVERE",
"AESER": "Y",
"AESHOSP": "Y",
"AEREL": "RELATED",
"AEACN": "DRUG INTERRUPTED",
"AESTDTC": "2025-03-05",
"AEOUT": "NOT RECOVERED/NOT RESOLVED"
}
]
}
Prompt: "Generate screening data with 30% screen failure rate for 100 subjects"
Output:
{
"screening_summary": {
"total_screened": 143,
"screen_passed": 100,
"screen_failed": 43,
"screen_failure_rate": 0.30
},
"screen_failures": [
{
"screening_id": "SCR-0015",
"failure_reason": "Inclusion criteria not met",
"failure_detail": "EGFR mutation negative",
"screening_date": "2025-01-20"
},
{
"screening_id": "SCR-0028",
"failure_reason": "Exclusion criteria met",
"failure_detail": "Prior immunotherapy within 6 months",
"screening_date": "2025-01-25"
}
]
}
Prompt: "Generate DM domain for 10 subjects as SDTM"
Output:
{
"domain": "DM",
"records": [
{
"STUDYID": "ONCO-2025-001",
"DOMAIN": "DM",
"USUBJID": "ONCO-2025-001-001-0001",
"SUBJID": "0001",
"SITEID": "001",
"RFSTDTC": "2025-01-22",
"RFENDTC": null,
"BRTHDTC": "1958-05-15",
"AGE": 66,
"AGEU": "YEARS",
"SEX": "M",
"RACE": "WHITE",
"ETHNIC": "NOT HISPANIC OR LATINO",
"ARMCD": "TRT",
"ARM": "ABC-123 + SOC",
"COUNTRY": "USA"
}
]
}
Prompt: "Generate LB domain with liver function tests for safety monitoring"
Output:
{
"domain": "LB",
"records": [
{
"STUDYID": "SAFE-001",
"DOMAIN": "LB",
"USUBJID": "SAFE-001-001-0042",
"LBSEQ": 1,
"LBTESTCD": "ALT",
"LBTEST": "Alanine Aminotransferase",
"LBCAT": "CHEMISTRY",
"LBORRES": "32",
"LBORRESU": "U/L",
"LBSTRESN": 32,
"LBSTRESU": "U/L",
"LBSTNRLO": 7,
"LBSTNRHI": 56,
"LBNRIND": "NORMAL",
"LBLOINC": "1742-6",
"LBBLFL": "Y",
"VISITNUM": 2,
"VISIT": "BASELINE"
}
]
}
Prompt: "Derive ADSL and ADTTE datasets from the SDTM data for this trial"
ADSL (subject-level analysis dataset with baseline characteristics):
{
"dataset": "ADSL",
"records": [
{
"STUDYID": "ONCO-2025-001", "USUBJID": "ONCO-2025-001-001-0001",
"SUBJID": "0001", "SITEID": "001", "TRT01P": "ABC-123 + SOC",
"AGE": 66, "SEX": "M", "RACE": "WHITE",
"RFSTDTC": "2025-01-22", "RFENDTC": "2025-07-15",
"EOSSTT": "COMPLETED", "DCSREAS": null,
"BMIBL": 24.3, "ECOGBL": 1
}
]
}
ADTTE (time-to-event analysis dataset):
{
"dataset": "ADTTE",
"records": [
{
"STUDYID": "ONCO-2025-001", "USUBJID": "ONCO-2025-001-001-0001",
"PARAMCD": "PFS", "PARAM": "Progression-Free Survival",
"AVAL": 182, "AVALU": "DAYS",
"CNSR": 0, "EVNTDESC": "Disease Progression (RECIST)",
"STARTDT": "2025-01-22", "ADT": "2025-07-23"
},
{
"STUDYID": "ONCO-2025-001", "USUBJID": "ONCO-2025-001-001-0002",
"PARAMCD": "OS", "PARAM": "Overall Survival",
"AVAL": 365, "AVALU": "DAYS",
"CNSR": 1, "EVNTDESC": "Censored (alive at cutoff)",
"STARTDT": "2025-01-29", "ADT": "2026-01-29"
}
]
}
TrialSim integrates with the Generative Framework for specification-driven generation at scale.
Use profile specifications to generate trial subject populations. The Profile Executor samples demographics meeting I/E criteria, generates baseline disease characteristics, applies randomization, and creates screening assessments.
Attach protocol journey specifications to create visit sequences. The Journey Executor generates protocol visits at specified windows, creates assessments per schedule, applies visit variance, and handles protocol deviations and early termination.
When generating across products, TrialSim entities are automatically linked:
| TrialSim Entity | Links To |
|---|---|
| Subject | PatientSim Patient (via SSN) |
| Site | NetworkSim Facility |
| Investigator | NetworkSim Provider |
| Conmed | RxMemberSim Fill (if applicable) |